




**JOHNS HOPKINS**  
BLOOMBERG SCHOOL  
*of* PUBLIC HEALTH



**Thomas Hartung & team**

Slides available



**Recent advances in the field**

# Thanking our sponsors

## Current



*Space for You!*

## Philanthropic



...and individuals



## Recent



CONFLICT  
OF  
INTEREST

 **frontiers**  
in Artificial Intelligence

**Editor**

 **frontiers**  
in Big Data

AstraZeneca 

MPS



ATCC



**AxoSim**  
Human Data, Faster.  
VP, shareholder

*in*sphero

Apellis

Pyrogen



A.I.



Consultant

Green Chemistry  
Advisory Panel


**ToxTRACK**

Consultant, shareholder

In preparation: Insilica LLC

# Working from home, Online meetings and teaching

Picture removed  
for copyright reasons



free  
each 13  
lectures




Fig. 1: Kuhn's Scientific Revolution Cycle (adapted from Kerry et al., 2008) and where the authors saw the state of regulatory toxicology in 2008 and now in 2021

Food for Thought ...

ALTEX 2021

## The State of the Scientific Revolution in Toxicology

Thomas Hartung<sup>1,2</sup> and Aristides M. Tsatsakis<sup>3</sup>



## Toxicity testing in the 21st century: progress in the past decade and future perspectives

Arch Toxicol 2019

D. Krewski<sup>1,2,4</sup> · M. E. Andersen<sup>3</sup> · M. G. Tyshenko<sup>2,4</sup> · K. Krishnan<sup>2,5</sup> · T. Hartung<sup>6,13</sup> · K. Boekelheide<sup>7</sup> · J. F. Wambaugh<sup>8</sup> · D. Jones<sup>9</sup> · M. Whelan<sup>10</sup> · R. Thomas<sup>8</sup> · C. Yauk<sup>11</sup> · T. Barton-Maclaren<sup>11</sup> · I. Cote<sup>12</sup>



**~50% of Americans and  
~60% of Europeans  
object to animal testing**

**Pressure is mounting**

**Picture removed  
for copyright reasons**

**Picture removed  
for copyright reasons**

**2002 EU cosmetics ban  
2006 Goal of EU REACH  
2016 Goal for US TSCA  
2019 Deadline 2035 by US EPA  
2021 Deadline 2027 by EFSA**

Change communication approach...  
...and move from war of faith to an engineering challenge

**Pictures removed for copyright reasons**

**Ethics**



**Bad Science**

Lack of reproducibility and predictivity

**Bad Economics**

Economic consequences and opportunities

It is still good to be on the right side of ethics and history!

# Animal Testing and its Alternatives – the Most Important Omics is Economics

*Lucy Meigs<sup>1,2</sup>, Lena Smirnova<sup>2</sup>, Costanza Rovida<sup>3</sup>, Marcel Leist<sup>3</sup> and Thomas Hartung<sup>2,3</sup>*



**Picture removed  
for copyright reasons**

**Economic considerations are underestimated**


**They promote and hinder implementation of NAM**

# The value of animal tests is strongly overestimated

- For the 9 most common OECD tox tests (acute and topical, eco – n = 2,839), reproducibility is 81%, 69% for toxic substances



- Mice and rat predict each other ~60% for systemic tox



- Miss some human effects
- Too long, too expensive, too much substance need
- New hazards not covered
- New products not applicable
- Mixtures and individual susceptibility not adequately covered

**Food for Thought...**

**ALTEX 2015, 32:79-100**

# **The Human Whole Blood Pyrogen Test – Lessons Learned in Twenty Years**



*Thomas Hartung*

**Invented 1995, Validated 2006 PyroDetect (Merck-Millipore)  
Accepted FDA 2009, European Pharmacopoeia 2010, USP 2017,  
ISO 2018**

**Implementation takes too long  
– little enforcement**



**Food for Thought ...**

**ALTEX 2021, 38:3-19**

# **Pyrogen Testing Revisited on Occasion of the 25<sup>th</sup> Anniversary of the Whole Blood Monocyte Activation Test**

*Thomas Hartung<sup>1,2</sup>*



Food for Thought ...

ALTEX 2020, 37:167-186

## New European Union Statistics on Laboratory Animal Use – What Really Counts!

*Francois Busquet<sup>1,2#</sup>, Andre Kleensang<sup>3#</sup>, Costanza Rovida<sup>1,4#</sup>, Kathrin Herrmann<sup>3</sup>, Marcel Leist<sup>1</sup> and Thomas Hartung<sup>1,3</sup>*



# Pyrogen testing

2005: ~160,000 rabbits

2008: ~170,000 rabbits

2015: 46,553

2016: 39,434

2017: 35,172



News 2021: PharmEur will phase out rabbits within 5a!

# Immunotoxicity - too much of a good thing...

- **Inflammation**
- **Pyrogenicity**
- **Sensitization**

**Pictures removed  
for copyright reasons**

- **Immunosuppression**
- **Developmental ImmunoTox**  
**= impaired or false response**

# Inflammation usually lacking *in vitro*

## Food for Thought ...

### Immunotoxicology: Challenges in the 21<sup>st</sup> Century and *In Vitro* Opportunities

Thomas Hartung<sup>1</sup> and Emanuela Corsini<sup>2</sup>



Strong evidence, e.g., for involvement of immune cells likely activated by translocation of bacteria (Su, 2002; Nolan, 2010) in the effects of classic hepatotoxicants (Laskin and Pendino, 1995; Leist et al., 1998; Luster et al., 2001): paracetamol, cocaine, nitrosamine, galactosamine, lead withdrawal, thioacetamide,  $\alpha$ -amanitin, actinomycin D, diethyl-dithiocarbamate, phalloidin, CCl<sub>4</sub>, cyproterone acetate, 1,2-dichlorobenzene, cadmium, allyl alcohol, heliotrine, ischemia-reperfusion, microcystine, and others.


**Picture removed  
for copyright reasons**

<https://www.gastroenterologyadvisor.com/liver/biomarkers-for-liver-damage-may-allow-for-early-identification-of-liver-toxicity-and-eventual-cancer/>

# Evaluation and Prevalidation of an Immunotoxicity Test Based on Human Whole-blood Cytokine Release



Ingrid Langezaal,<sup>1,2,3</sup> Sebastian Hoffmann,<sup>2</sup> Thomas Hartung<sup>2,4</sup> & Sandra Coecke<sup>1</sup>



**Immunotoxic disturbance of reaction to bacterial stimulation**  
**Simple, robust test**  
**Human primary cells**  
**Lymphocyte and monocyte endpoints**



**Toxicol. In Vitro 2001, 15:313-318**

Langezaal et al., ATLA 2002, 30:581-595

Whole blood cytokine response as a measure of immunotoxicity

I. Langezaal<sup>a,b</sup>, S. Coecke<sup>b</sup>, T. Hartung<sup>a,\*</sup>

# ALTERNATIVES TO DEVELOPMENTAL IMMUNOTOXICITY TESTING (DIT) WORKING GROUP



- Fenna Sillé
- Helena Hogberg
- Katya Tsaïoun



## Academia / Research Institutes:

- Johanna Gostner, PhD (Biocenter, Medical University of Innsbruck)
- Emanuela Corsini, PhD (University of Milan)
- Dori R. Germolec, PhD (NTP/NIEHS)




## Regulatory:

- Suzanne Fitzpatrick, PhD, DABT (FDA)
- Cameron Bowes, PhD (Health Canada - regulatory)
- David Lefebvre, PhD (Health Canada – Method development)
- O'hara, Shifawn (Health Canada)



## Industry & End-users:

- Leigh Ann Burns-Naas, PhD, DABT, ERT, ATS (Magnolia Toxicology Consulting, LLC)
- Mark Collinge, PhD (Pfizer)
- Vic Johnson, PhD (BRT Labs)



## Librarian:

Robert Wright (JHU)



**Picture removed  
for copyright reasons**

- Opinion article
- Scoping review
- **May 4-5, 2021: Virtual mini-workshop #1: “Identification of Key Molecular and Biological events in Developmental Immunotoxicity”**
- **March 26-30, 2022: SOT (San Diego): Workshop Session “Current Status and Future Outlook on Developmental Immunotoxicity Testing.”**


# Call to Action

# We have the tools 1

## Evolution of Cell Culture - high-tech & business opportunity

# INSIGHTS

Microfluidic systems can connect multiple types of human tissues and mimic aspects of human physiology to improve evaluations of drug responses.



PERSPECTIVES

MEDICINE

## Human microphysiological systems for drug development

Organs-on-chips could be used to assess drug efficacy and support personalized medicine

Science 16 Sep 2021




Marx et al., Biology-inspired micro-physiological system approaches to solve the prediction dilemma of substance testing using animals. ALTEX 2016, 33:272-321.



Marx et al., Biology-inspired microphysiological systems to advance medicines for patient benefit and animal welfare. ALTEX 2020, 37:365-394 .



Current Opinion in Biotechnology



**MPS WORLD SUMMIT**  
CONNECT, EXCHANGE, EDUCATE

**~45 organizations plus  
Scientific Advisory Board**

**\$450k from NCATS**

**Forming an International Society  
and Conference Series**

**Virtual 24 Jun & 9 Dec '21  
New Orleans 30 May-3 Jun '22  
Hosts: Suzie Fitzpatrick, FDA  
Thomas Hartung, Hopkins  
Don Ingber, Harvard**

**<https://mpsworldsummit.com>**



At ESTIV 2018 CAAT/ESTIV symposium

## GCCP 2.0

Draft published  
350 stakeholder  
comments integrated

- ALTEX 1'2022
- Editor workshop 2022
- Funding bodies

Letter

ALTEX 2020, 37: 490-492

## Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0) – Draft for Stakeholder Discussion and Call for Action

*David Pamies<sup>1</sup>, Marcel Leist<sup>2,3</sup>, Sandra Coecke<sup>4</sup>, Gerard Bowe<sup>4</sup>, Dave Allen<sup>5</sup>, Gerhard Gstraunthaler<sup>6</sup>,  
Anna Bal-Price<sup>4</sup>, Francesca Pistollato<sup>4</sup>, Rob deVries<sup>7,8</sup>, Thomas Hartung<sup>2,9</sup> and Glyn Stacey<sup>10,11,12</sup>*


Register at:  
[CAAT@jhu.edu](mailto:CAAT@jhu.edu)

**Picture removed  
for copyright reasons**

- **Quality of cell model (GCCP)**
- **Quality of reporting (GIVReSt)**
- **Quality of results (validation)**

Picture removed  
for copyright reasons

# DEVELOPMENTAL NEUROTOXICITY





# DNT from *in vivo* towards *in vitro*



ISTNET Workshop



Expert Group on DNT



Guidance Document

2005

2010

2015

2020



Test Readiness



STAR grant



DNT Reference Compounds



# BrainSpheres: iPSC-derived human organotypic brain cultures



- All cell types but micro-glia
- 350 um diameter
- Reproducible in size and composition
- Myelination
- Genetic background from patient iPSC



# BRAIN ORGANOIDS

STANDARDIZED  
HUMAN 3D  
DEVELOPMENT  
FROM IPSC



GLIA CELLS,  
MYELINATION  
+ ADDED MICRO-  
GLIA



INFECTION  
CANCER GRAFTS  
TOXICITY



GENETIC  
BACKGROUNDS,  
+ RISK GENES,  
REPAIR



+ REPORTER GENES  
GENE X



ENVIRONMENT  
MIXTURES  
FUNCTIONAL




ASSAYS:

NEURITES,  
SYNAPSES, 3D  
ORGANOID  
EKG




INTELLIGENCE  
(O.I.)



# Myelination

- 40% axons myelinated
- Allows studying de- and re-myelination



International Journal of  
*Molecular Sciences*

**Int. J. Mol. Sci. 2021, 22, 9473**



*Article*

## **Human iPSC-Derived Model to Study Myelin Disruption**

Megan Chesnut <sup>1</sup>, H el ene Paschoud <sup>2</sup>, Cendrine Repond <sup>2</sup>, Lena Smirnova <sup>1</sup>, Thomas Hartung <sup>1,3</sup>,  
Marie-Gabrielle Zurich <sup>2,4</sup>, Helena T. Hogberg <sup>1,\*</sup> and David Pamies <sup>1,2,4,\*</sup>



International Journal of  
*Molecular Sciences*


**Int. J. Mol. Sci. 2021, 22, 7929**



*Review*

## **Human Oligodendrocytes and Myelin In Vitro to Evaluate Developmental Neurotoxicity**

Megan Chesnut <sup>1</sup>, Thomas Hartung <sup>1,2</sup>, Helena Hogberg <sup>1,\*</sup> and David Pamies <sup>1,3,4,\*</sup>



# DNT in human brain organoids

 **frontiers** **Front Cell Neurosci 2020**

## Antidepressant Paroxetine exerts developmental neurotoxicity in an iPSC-derived 3D human brain model

Xiali Zhong<sup>1,2</sup>, Georgina Harris<sup>1</sup>, Lena Smirnova<sup>1</sup>, Valentin Zufferey<sup>3</sup>, Rita Sa<sup>4</sup>, Fabiele Baldino Russo<sup>5</sup>, Patricia C. Baleeiro Beltrao Braga<sup>3</sup>, Megan Chesnut<sup>1</sup>, Marie-Gabrielle Zurich<sup>3</sup>, Helena Hogberg<sup>1</sup>, Thomas Hartung<sup>6,7</sup>, David Pamies<sup>3,1\*</sup>



**Tox Appl Pharmacol 2018**



## Rotenone exerts developmental neurotoxicity in a human brain spheroid model

David Pamies<sup>a</sup>, Katharina Block<sup>a</sup>, Pierre Lau<sup>b</sup>, Laura Gribaldo<sup>b</sup>, Carlos A. Pardo<sup>c</sup>, Paula Barreras<sup>c</sup>, Lena Smirnova<sup>a</sup>, Daphne Wiersma<sup>a</sup>, Liang Zhao<sup>a,d</sup>, Georgina Harris<sup>a</sup>, Thomas Hartung<sup>a,e</sup>, Helena T. Hogberg<sup>a,\*</sup>

Archives of Toxicology  
<https://doi.org/10.1007/s00204-020-02903-2>


**Arch Toxicol 2021**




**ORGAN TOXICITY AND MECHANISMS**

## Organophosphorus flame retardants are developmental neurotoxicants in a rat primary brainsphere in vitro model

# CHD8 and chlorpyrifos functional synergy




## CHLORPYRIFOS



## CHLORPYRIFOS-OXON



# GxE



## Functional and Molecular signatures


Lena Smirnova

# CHD8 knockout BrainSpheres (CRISPR-CAS9) as disease model

Modafferi et al., EHP 2021

## Gene–Environment Interactions in Developmental Neurotoxicity: a Case Study of Synergy between Chlorpyrifos and CHD8 Knockout in Human BrainSpheres

Sergio Modafferi,<sup>1,2\*</sup> Xiali Zhong,<sup>1,3\*</sup> Andre Kleensang,<sup>1</sup> Yohei Murata,<sup>1,4</sup> Francesca Fagiani,<sup>1,5,6</sup> David Pamies,<sup>1,7</sup> Helena T. Hogberg,<sup>1</sup> Vittorio Calabrese,<sup>2</sup> Herbert Lachman,<sup>8,9</sup> Thomas Hartung,<sup>1,10</sup> and Lena Smirnova<sup>1</sup> 



### CHD8/CPF synergy in perturbation of energy metabolism, one carbon metabolism, L-a-Hydroxyglutaric acid and tryptophan synthesis

|                          | ASD patients |       |       | BrainSpheres |         |         |
|--------------------------|--------------|-------|-------|--------------|---------|---------|
|                          | Blood        | Urine | Brain | CHD8         | CPF/CPO | Synergy |
| Dopamine                 |              |       | ↓     | ↓            | -       | -       |
| Choline                  |              |       | ↓     | ↓            | ↓       | ↓ ↓     |
| Tryptophan               | -            | ↓ ↑   | -     |              |         | ↑       |
| Kynurenic acid           | ↓            | -     | -     | ↑            |         | ↑ ↑     |
| Lactic acid              | ↑ ↓          | ↓     |       |              |         | ↑       |
| L-Alanine                |              |       |       |              | ↑       |         |
| SAH                      | ↑            | ↑     |       | ↑            |         | ↑       |
| L-a-Hydroxyglutaric acid |              | ↑     |       |              |         | ↑       |




Lachman



Smirnova

**CHLORPYRIFOS**  
CHLORPYRIFOS-OXON





# September 2019



POLICY-ISH

## EPA Chief Pledges To Severely Cut Back On Animal Testing Of Chemicals

2:43



### News Releases

News Releases from Region 03

## EPA Awards Nearly \$850,000 to Johns Hopkins University to Advance Research on Alternative Methods to Animal Testing



Smirnova,  
Hartung,  
Berlinicke,  
Gracias




Sep 2021

**CAAT receives \$300k grant from FDA for DNT-MPS (already funded by EPA) through the JH Center of Excellence in Regulatory Science and Innovation**

# 6-in-1 BrainSphere assay to test Neurodevelopment

Neuronal differentiation  
Myelination  
Neurite outgrowth  
Synaptogenesis  
Glia migration & Gliosis  
Neural network (E-phys)



CRISPR/C

Reporter/  
Fusion  
proteins



## Mini- Brainbow

Neurons

Astrocytes

Oligodendrocytes

Synapses

3D electrophys



High content imaging  
Toxicant/drug screening

# COVID-19 – Prime Time for Microphysiological Systems, as Illustrated for the Brain

Ian Kang<sup>1</sup>, Lena Smirnova<sup>1</sup>, Jens H. Kuhn<sup>2</sup>, Helena T. Hogberg<sup>1</sup>, Nicole C. Kleinstreuer<sup>3</sup> and Thomas Hartung<sup>1,4</sup>



*ALTEX preprint  
published June 26, 2020  
doi:10.14573/altex.2006111*

Short communication

## Infectability of Human BrainSphere Neurons Suggests Neurotropism of SARS-CoV-2

*C. Korin Bullen<sup>1,#</sup>, Helena Therese Hogberg<sup>2,#</sup>, Asli Bahadirli-Talbott<sup>1</sup>, William R. Bishai<sup>1</sup>, Thomas Hartung<sup>2,3,4</sup>, Casey Keuthan<sup>5</sup>, Monika M. Looney<sup>1</sup>, Andrew Pekosz<sup>4</sup>, July Carolina Romero<sup>2</sup>, Fenna C. M. Sillé<sup>2,6</sup>, Peter Um<sup>1</sup> and Lena Smirnova<sup>2,#</sup>*

FINANCIAL TIMES

HOME WORLD US COMPANIES TECH MARKETS GRAPHICS OPINION WORK & CAREERS LIFE & ARTS HOW TO SPEND IT

**CORONAVIRUS BUSINESS UPDATE**  
Get 30 days' complimentary access to our Coronavirus Business Update newsletter

Latest on Coronavirus treatment

- Germany to take stake in Covid-19 vaccine hopeful CureVac
- World economy's challenge laid bare by new data
- EU to spend billions of euros to secure coronavirus vaccine

Coronavirus treatment [+ Add to myFT](#)

### Coronavirus could infect human brain and replicate, US study shows

Johns Hopkins University research adds to concern about poorly understood neurological symptoms

[Twitter](#)  
[Facebook](#)  
[LinkedIn](#)  
[Save](#)

Presence of ACE2 receptor at all stages of mini-brain development

Some neural cells infected

Replication shown by PCR and confocal microscopy


# Another scientific revolution

**Picture removed  
for copyright reasons**

# Data produced world-wide

**5000% between 2010 and 2020**

*(Source: Forbes)*




© Statista 2021

**84% of data in the world were created in the last 6 years**

Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2025 *(in zettabytes)*

# Machine Learning in Biology




**Fig. 1 | Exponential increase of ML publications in biology.** The number of ML publications per year is based on Web of Science from 1996 onwards using the topic category for “machine learning” in combination with each of the following terms: “biolog\*”, “medicine”, “genom\*”, “prote\*”, “cell\*”, “post translational”, “metabolic” and “clinical”.

Picture removed  
for copyright reasons

<https://universitybusiness.com/revolutionary-ed-tech-creates-new-challenges-campus-leaders/attachment/artificial-intelligence-and-future-concept/>

Walsh et al. Nat Meth 2021

# Novel tools Big Data for A.I.



# A.I. = Making big sense of BIG DATA

**Picture removed  
for copyright reasons**


<https://theamericangenius.com/editorials/big-data-is-watching-you-some-will-panic-others-will-rejoice/>

**Picture removed  
for copyright reasons**

**Volume  
Variety  
Velocity**

<https://www.e-marketing.fr/Thematique/data-1091/big-data-2223/Breves/Tout-faut-savoir-big-data-363012.htm>

**...is more than a large EXCEL sheet!**



# A.I. use cases

# *IMAGE RECOGNITION: High-content Imaging, especially in pathology*




ALTEX 2014, 31:479-493

## **t4 Workshop Report\***

### **Current Approaches and Future Role of High Content Imaging in Safety Sciences and Drug Discovery**

*Erwin van Vliet<sup>1</sup>, Mardas Daneshian<sup>2</sup>, Mario Beilmann<sup>3</sup>, Anthony Davies<sup>4</sup>, Eugenio Fava<sup>5</sup>, Roland Fleck<sup>6</sup>, Yvon Julé<sup>7</sup>, Manfred Kansy<sup>8</sup>, Stefan Kustermann<sup>8</sup>, Peter Macko<sup>9</sup>, William R. Mundy<sup>10</sup>, Adrian Roth<sup>8</sup>, Imran Shah<sup>11</sup>, Marianne Uteng<sup>12</sup>, Bob van de Water<sup>13</sup>, Thomas Hartung<sup>2,14</sup> and Marcel Leist<sup>2\*</sup>*

**Picture removed  
for copyright reasons**



# A.I. use cases


# Mining publications

# Sysrev.com

# TOXTRACK

## Semi-automated systematic review:

- Auto-extract from e.g. PubMed
- Auto-annotate papers
- Auto-analyze clustering of papers
- Learn from manual inclusion / exclusion
- Automated inclusion / exclusion suggestions



Alexandra Maertens



# Making big sense of

Picture removed for copyright reasons

**Research Article**

### Evaluation of the Global Performance of Eight *In Silico* Skin Sensitization Models Using Human Data

Emily Golden<sup>1</sup>, Donna S. Macmillan<sup>2</sup>, Greg Dawerlan<sup>3</sup>, Petra Kern<sup>4</sup>, Thomas Hartung<sup>1,4</sup> and Alexandra Maertens<sup>1</sup>

<sup>1</sup>Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; <sup>2</sup>Chas Limited, Leek, UK; <sup>3</sup>Procter & Gamble NV, Beve, Belgium; <sup>4</sup>CAAT Europe, University of Konstanz, Konstanz, Germany

**Chemical Research in Toxicology**

pubs.acs.org/CR

### Mapping Chemical Respiratory Sensitization: How Useful Are Our Current Computational Tools?

Emily Golden, Mikhail Maertens, Thomas Hartung, and Alexandra Maertens\*

Cite This: <https://doi.org/10.1021/acs.chemres.0c00120> | [Read Online](#)

Arch Toxicol  
DOI: 10.1007/s00204-016-1695-4

**MOLECULAR TOXICOLOGY**

### Metabolomic network analysis of estrogen-stimulated MCF-7 cells: a comparison of overrepresentation analysis, quantitative enrichment analysis and pathway analysis versus metabolite network analysis

Alexandra Maertens<sup>1</sup>, Mounir Bouhid<sup>2</sup>, Liang Zhao<sup>2</sup>, Shelly Odwin-DaCosta<sup>1</sup>, Andre Kleensang<sup>3</sup>, James D. Yager<sup>3</sup>, Thomas Hartung<sup>1,3,4</sup>

**ACS Sustainable Chemistry & Engineering**

pubs.acs.org/journal/esteng

### Avoiding Regrettable Substitutions: Green Toxicology for Sustainable Chemistry

Alexandra Maertens, Emily Golden, and Thomas Hartung\*

Cite This: <https://doi.org/10.1021/acsschemeng.8b09435> | [Read Online](#)

**frontiers in Genetics**

ORIGINAL RESEARCH  
published: 12 November 2018  
doi: 10.3389/fgen.2018.00508

### Weighted Gene Correlation Network Analysis (WGCNA) Reveals Novel Transcription Factors Associated With Bisphenol A Dose-Response

Alexandra Maertens<sup>1</sup>, Vy Tran<sup>1</sup>, Andre Kleensang<sup>1</sup> and Thomas Hartung<sup>1,2\*</sup>

**SCIENTIFIC REPORTS**  
nature research

**OPEN** **Functionally Enigmatic Genes in Cancer: Using TCGA Data to Map the Limitations of Annotations**

Alexandra Maertens<sup>1,2</sup>, Vy H. Tran<sup>1,2</sup>, Mikhail Maertens<sup>3</sup>, Andre Kleensang<sup>4</sup>, Thomas H. Luechtefeld<sup>1,2</sup>, Thomas Hartung<sup>1,2</sup> & Channing J. Paller<sup>4\*</sup>

**frontiers in Artificial Intelligence**

ORIGINAL RESEARCH  
published: 13 May 2021  
doi: 10.3389/fnai.2021.674370

### Similarities and Differences in Gene Expression Networks Between the Breast Cancer Cell Line Michigan Cancer Foundation-7 and Invasive Human Breast Cancer Tissues

Vy Tran<sup>1</sup>, Robert Kim<sup>1</sup>, Mikhail Maertens<sup>1</sup>, Thomas Hartung<sup>1,2,3</sup> and Alexandra Maertens<sup>1\*</sup>



# EXPOSOME COLLABORATIVE

## Example Big Data and making sense of it

**ALTEX 2020, 37, 3-23**

*“Progress is impossible without change, and those  
who cannot change their minds cannot change anything.”*

George Bernard Shaw (1856-1950)

*“If you change the way you look  
at things, the things you look at change.”*


Wayne Dyer (1940-2015)

**Food for Thought ...**

### **The Exposome – a New Approach for Risk Assessment**

*Fenna Sillé<sup>1</sup>, Spyros Karakitsios<sup>2</sup>, Andre Kleensang<sup>1</sup>, Kirsten Koehler<sup>1</sup>, Alexandra Maertens<sup>1</sup>,  
Gary W. Miller<sup>3</sup>, Carsten Prasse<sup>1</sup>, Lesliam Quiros-Alcala<sup>1</sup>, Gurumurthy Ramachandran<sup>1</sup>, Stephen M. Rappaport<sup>4</sup>,  
Ana M. Rule<sup>1</sup>, Denis Sarigiannis<sup>2,5</sup>, Lena Smirnova<sup>1</sup> and Thomas Hartung<sup>1,6</sup>*





# A.I. use cases



Tom Luechtefeld

# The map of the chemical universe

**Similarity =  
proximity**



**ARTIFICIAL  
INTELLIGENCE**  
**10 million structures**  
**74 properties**  
**600k chemicals with data**

Picture removed  
for copyright reasons

9 most common toxicity tests  
190,000 chemical's hazard  
cross-validation:  
87% correct

<https://sfmagazine.com/technotes/february-2019-wipo-u-s-and-china-lead-the-world-in-ai-innovation/>

ACCEPTED MANUSCRIPT

## Machine learning of toxicological big data enables read-across structure activity relationships (RASAR) outperforming animal test reproducibility



Thomas Luechtefeld, Dan Marsh, Craig Rowlands, Thomas Hartung ✉

Toxicological Sciences, kfy152, <https://doi.org/10.1093/toxsci/kfy152>

Published: 11 July 2018



TOXICOLOGY Science, 12 Feb 2016

### *A crystal ball for chemical safety*

By comparing new chemicals to known compounds, toxicologists seek early hazard warnings

nature International weekly journal of science

Home | News & Comment | Research | Careers & Jobs | Current Issue | Archive | Audio & Video | For Authors

News & Comment | News | 2018 | February | Article

NATURE | NEWS

#### Legal tussle delays launch of huge toxicity database

Health risks of nearly 10,000 chemicals charted to help predict toxicity of untested substances.

Natasha Gilbert

nature International weekly journal of science

Home | News & Comment | Research | Careers & Jobs | Current Issue | Archive | Audio & Video | For Authors

News & Comment | News

#### Software beats animal tests at predicting toxicity of chemicals

Machine learning on extension of safety data improves automated assessments.

By Vanessa Zainzinger | Jul 11, 2018, 11:00 AM

Science Home News Journals Topics Careers Advertisement

Login | My account | Contact us



An estimated 3 million to 4 million rabbits, rats, and other animals are used annually around the world for chemical safety tests. CAMERON DOWNING/ISTOCKPHOTO

### New digital chemical screening tool could help eliminate animal testing

By Vanessa Zainzinger | Jul 11, 2018, 11:00 AM

**Pictures removed  
for copyright reasons**

**Uses chemical similarity  
(network effect)**


**Uses transfer learning (74  
labels)**

**Boosted accuracy by ~10%**

- **Combining read-across with machine-learning**
- **Very large database**
- **Nine OECD test predicted**
- **87% accuracy for 190,000 chemicals with known classifications**
- **81% reproducibility of respective animal tests**

# The implementation: Version 2.0 released 2020 - deep learning, applicability domains, certainty, potency

- **Accepted for Australian Industrial Chemical Legislation 2020**
- **Under evaluation by FDA**



The screenshot shows the top navigation bar of the UL website with the UL logo, links for Offerings, Industries, Insights, News, Events, About UL, and Resources, and a search box. Below the navigation is a hero image of a scientist in a lab coat. Overlaid on the image is a white square containing a chemical structure icon. To the right of the image, the text reads 'TOOL' followed by 'UL Cheminformatics Tool Kit'. Below this is a paragraph describing the tool's capabilities: 'With a curated database of 70 million structures and 80,908 chemicals with 833,844 labeled hazard endpoints, our digital solution utilizes an advanced algorithm, machine learning, and analysis of millions of chemical combinations to predict chemical hazards.' At the bottom of the text area is a blue button labeled 'Learn more'.

UL Offerings Industries Insights News Events About UL Resources

**TOOL**

## UL Cheminformatics Tool Kit

With a curated database of 70 million structures and 80,908 chemicals with 833,844 labeled hazard endpoints, our digital solution utilizes an advanced algorithm, machine learning, and analysis of millions of chemical combinations to predict chemical hazards.

[Learn more](#)

# Ongoing RASAR developments

79% (n=131) and 80% (n=375) accuracy in predicting  
**HUMAN skin sensitization** (Golden et al., ALTEX, 2020)

38,250 predictions for 4,729 food-relevant substances  
83% accurate (n=139) (Fu et al., submitted)

Preliminary (Luechtefeld et al., unpublished):

**Reproductive Tox** 82% accurate (n=1152)

**Carcinogenicity** 75% accurate (n=950)

**Androgen effect** 98% accurate (n=8492)

**Estrogen transactivation** 80% accurate (n=1660)

EU ONTOX project (\$20 million, 2021-2026) to expand  
to liver, kidney and developing brain



**Picture removed  
for copyright reasons**

# Green toxicology

– the toxicology aspects of green chemistry

Picture removed  
for copyright reasons

Another use of  
alternatives methods



SOT | Society of  
Toxicology  
www.toxsci.oxfordjournals.org



TOXICOLOGICAL SCIENCES, 161(2), 2018, 285–289

doi: 10.1093/toxsci/kfx243

Advance Access Publication Date: December 18, 2017

Editorial



EDITORIAL

## Green Toxicology—Know Early About and Avoid Toxic Product Liabilities

Alexandra Maertens\* and Thomas Hartung\*,†,1

# The dark side of A.I.

**Picture removed  
for copyright reasons**

- Data and energy need
- You always get a result, whether the information is in the data or not
- Challenges: Explainable A.I., Causality, Validation,  
Bias in data = bias in results

# Human-in-the-loop

**Pictures removed  
for copyright reasons**

**Same approach as self-driving cars....  
...but A.I. is far safer than humans!**



***“AI will not replace toxicologists,  
but those who don’t use AI will be  
replaced by those who do”***

**Stefan Platz, AstraZeneca  
Senior Vice President of Clinical  
Pharmacology and Safety Sciences**

# EVIDENCE INTEGRATION



## Food for Thought ... Integrated Testing Strategies for Safety Assessments

*Thomas Hartung<sup>1,2</sup>, Tom Luechtefeld<sup>1</sup>, Alexandra Maertens<sup>1</sup>, and Andre Kleensang<sup>1</sup>*

### *In vivitrosi*

Aka Integrated Testing  
Strategies, IATA,  
Defined Approaches...

$$1 + 1 > 2$$

Picture removed  
for copyright reasons



# A cultural problem in science

**Nobody likes to criticize their tools**

**This holds especially for the regulating and the regulated community.**

<https://www.inc.com/minda-zetlin/7-reasons-being-self-critical-can-make-you-more-successful.html>



# EVIDENCE INTEGRATION 2: Evidence-based Toxicology, systematic reviews, risk assessment...

## 2006 Article

Human & Experimental Toxicology (2006) 25: 497-513  
www.sagepublications.com

### Toward an evidence-based toxicology

S Hoffmann\* and T Hartung

European Commission, JRC – Joint Research Centre, Institute for Health & Consumer Protection, ECVAM – European Centre for the Validation of Alternative Methods, 21020 Ispra (VA), Italy



## 2007 Conference




## 2009 Chair Hopkins

2011 Organization  
[www.ebtox.org](http://www.ebtox.org)




# The explosion of systematic reviews



- **Huge progress from almost nothing in the 90s**
- **Explosion in publications**
- **Thousands of people now engaged in EBT**
- **Stakeholders at every level, everywhere**

# Main steps

Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: A scoping review



# Key publications

## A primer on systematic reviews in toxicology

Sebastian Hoffmann<sup>1,13</sup> · Rob B. M. de Vries<sup>2</sup> · Martin L. Stephens<sup>1</sup> · Nancy B. Beck<sup>3</sup> · Hubert A. A. M. Dirven<sup>4</sup> · John R. Fowle III<sup>5</sup> · Julie E. Goodman<sup>6</sup> · Thomas Hartung<sup>7</sup> · Ian Kimber<sup>8</sup> · Manoj M. Lalu<sup>9</sup> · Kristina Thayer<sup>10</sup> · Paul Whaley<sup>11</sup> · Daniele Wikoff<sup>12</sup> · Katya Tsaïoun<sup>1</sup> 



## Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: A scoping review



Gbeminiyi O. Samuel<sup>a</sup>, Sebastian Hoffmann<sup>b</sup>, Robert A. Wright<sup>c</sup>, Manoj Mathew Lalu<sup>d</sup>, Grace Patlewicz<sup>e,1</sup>, Richard A. Becker<sup>f</sup>, George L. DeGeorge<sup>g</sup>, Dean Fergusson<sup>d</sup>, Thomas Hartung<sup>a</sup>, R. Jeffrey Lewis<sup>h</sup>, Martin L. Stephens<sup>a,\*</sup>



## A Systematic Review to Compare Chemical Hazard Predictions of the Zebrafish Embryotoxicity Test With Mammalian Prenatal Developmental Toxicity

Sebastian Hoffmann ,<sup>\*,†,1</sup> Bianca Marigliani,<sup>‡</sup> Sevcan Gül Akgün-Ölmez,<sup>§</sup> Danielle Ireland,<sup>¶</sup> Rebecca Cruz,<sup>||</sup> Francois Busquet,<sup>|||</sup> Burkhard Flick ,<sup>||||</sup> Manoj Lalu,<sup>#</sup> Elizabeth C. Ghandakly,<sup>\*\*</sup> Rob B.M. de Vries,<sup>\*,††</sup> Hilda Witters,<sup>‡‡</sup> Robert A. Wright,<sup>§§</sup> Metin Ölmez,<sup>¶¶</sup> Catherine Willett,<sup>##</sup> Thomas Hartung,<sup>\*\*\*</sup> Martin L. Stephens,<sup>\*</sup> and Katya Tsaïoun 



## FORUM SERIES, PART III

# A Toxicology for the 21st Century—Mapping the Road Ahead

Thomas Hartung<sup>1</sup>

*Johns Hopkins University, Bloomberg School of Public Health, Department for Environmental Health Sciences, Center for Alternatives to Animal Testing,  
Chair for Evidence-based Toxicology, Baltimore, MD 21231*

Received February 19, 2009; accepted March 13, 2009



PoT / AoP



The landmark publication ...toxicology for the 21st century in 2007 has created an atmosphere of departure in our field. The alliances formed, symposia and meetings held and the articles following are remarkable, indicating that this is an idea whose time has come. Most of the discussion centers on the technical opportunities to **map pathways of toxicity** and the financing of the program. Here, the other part of the work ahead shall be discussed, that is, the focus is on **regulatory implementation** once the technological challenges are managed, but we are well aware that the technical aspects of what the National Academy of Science report suggests still need to be addressed: **A series of challenges are put forward which we will face in addition to finding a technical solution (and its funding) to set this vision into practice.**

## CHALLENGES

### TESTING STRATEGIES INSTEAD OF INDIVIDUAL TESTS

- ITS, IATA, Defined Approaches

### STATISTICS AND MULTIPLE TESTING

- A.I. evidence Integration

### THRESHOLD SETTING

- TTC, safety vs. adversity

### WHAT TO VALIDATE AGAINST?

- Mechanistic validation

### HOW TO OPEN UP REGULATORS FOR CHANGE?

- Evidence-based Toxicology

### THE GLOBAL DIMENSION

- Ongoing (World Conferences, PanAmerican, MPS-WS)

### QUALITY ASSURANCE FOR THE NEW APPROACH

- GCCP 2.0, Good In Vitro Reporting Standards, Good Read-Across Practice

### HOW TO CHANGE WITH STEP BY STEP DEVELOPMENTS

### BECOMING NOW AVAILABLE?

- Probabilistic Risk Assessment (Workshop Italy 4-6 Jul 2022)

### CHALLENGES TO BE TACKLED

### HOW TO ORGANIZE TRANSITION?

### MAKING IT A WIN/WIN/WIN SITUATION

Food for Thought ...

## Thresholds of Toxicological Concern – Setting a Threshold for Testing Below Which There Is Little Concern

Thomas Hartung



## Food for Thought ... Mechanistic Validation

Thomas Hartung<sup>1,2</sup>, Sebastian Hoffmann<sup>2,3</sup>, and Martin Stephens<sup>1</sup>



Food for Thought ...

## Toward Good *In Vitro* Reporting Standards

Thomas Hartung<sup>1,2</sup>, Rob de Vries<sup>3</sup>, Sebastian Hoffmann<sup>4</sup>, Helena T. Hogberg<sup>1</sup>, Lena Smirnova<sup>1</sup>, Katya Tsaïoun<sup>1</sup>, Paul Whaley<sup>5</sup> and Marcel Leist<sup>2</sup>



t<sup>4</sup> report\*

## Toward Good Read-Across Practice (GRAP) Guidance

Nicholas Ball<sup>15</sup>, Mark T. D. Cronin<sup>25</sup>, Jie Shen<sup>25</sup>, Karen Blackburn<sup>4</sup>, Ewan D. Booth<sup>5</sup>, Mounir Bouhifd<sup>6</sup>, Elizabeth Donley<sup>7</sup>, Laura Egnash<sup>7</sup>, Charles Hastings<sup>8</sup>, Daland R. Juberg<sup>1</sup>, Andre Kleensang<sup>6</sup>, Nicole Kleinstreuer<sup>9</sup>, E. Dinant Kroese<sup>10</sup>, Adam C. Lee<sup>11</sup>, Thomas Luechtefeld<sup>6</sup>, Alexandra Maertens<sup>6</sup>, Sue Marty<sup>1</sup>, Jorge M. Naciff<sup>4</sup>, Jessica Palmer<sup>7</sup>, David Pamies<sup>6</sup>, Mike Penman<sup>12</sup>, Andrea-Nicole Richarz<sup>2</sup>, Daniel P. Russo<sup>13</sup>, Sharon B. Stuard<sup>4</sup>, Grace Patlewicz<sup>14</sup>, Bennard van Ravenzwaay<sup>10</sup>, Shengde Wu<sup>4</sup>, Hao Zhu<sup>13</sup> and Thomas Hartung<sup>6,13</sup>



**Pictures removed  
for copyright reasons**

***We have most tools but we do not know how to change.***

***The roadblocks are not scientific but economic & legal.***

***Validation is as much a hurdle as it is enabling.***

***Change is more likely to come from politics than science***

***The difficulty lies not in the new ideas,  
but in escaping from the old ones.***

**John Maynard Keynes**

**(1883 - 1946)**

**Pictures removed  
for copyright reasons**

**Slides available**

